Trichostatin A (TSA)

目录号:S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献24篇:

客户使用该产品的6个实验数据:

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系,包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖,平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系,抑制HDAC活性,平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同,Trichostatin A 抑制这些HDACs,且抑制程度相似, IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞,通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体,而诱导转化生长因子βⅡ型受体(TβRII) 表达,复合体与TβRII 启动子的DNA片段结合,伴随着Sp1乙酰化,且与复合体相关的HDAC数理全部降低。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M2PZfWZ2dmO2aX;uJGF{e2G7 Moi3NE44|ryP MkDVNlRp M3TzXoV1cGGwb3y= MVzlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm NEnsTHIzPTd6N{C3PS=>
TE13 M4HWT2Z2dmO2aX;uJGF{e2G7 MkCwNE4{|ryP M{DnW|I1cA>? M1rke5VxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs M2DSUVI2PTd7Nk[1
TE13 M1;uN2Fxd3C2b4Ppd{BCe3OjeR?= NYX1SmZ3OC5|zszN M3vNN|I1cA>? M17OcYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MUGyOVU4QTZ4NR?=
MEFs MmW4SpVv[3Srb36gRZN{[Xl? M2ja[lXPxE1? NV3JfGpCOT[q NIDsbG5qdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? NEfm[JUzPTR6Mk[zOC=>
SW480  NYHsb3h2TnWwY4Tpc44hSXO|YYm= M4rNVlAvOc7:TR?= NXHWcpVnPDiq M4LBSmROW09? MWTy[ZZmenOnczDFUXQ> NHj1WVEzPTR|NEm5Oy=>
PC3  MkW4SpVv[3Srb36gRZN{[Xl? NXnkcJZHOC5zzszN MkH2OFhp MYHEUXNQ Mor3doV3\XK|ZYOgSW1V NGfBbWMzPTR|NEm5Oy=>
SW480  MUPGeY5kfGmxbjDBd5NigQ>? M1PDZlAvOc7:TR?= NVewVFZNPDiq M2rNfmROW09? MmLWZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w NFrXfIUzPTR|NEm5Oy=>
PC3  M4T2XGZ2dmO2aX;uJGF{e2G7 NFPBbYExNjIQvF2= Mmf1OFhp NFPFSmhFVVOR M{HNd4F1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MlPINlU1OzR7OUe=
SW480  MnqzSpVv[3Srb36gRZN{[Xl? MlTxNE4y|ryP MX:0PIg> NXm5RnA{TE2VTx?= MVrpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M3u0N|I2PDN2OUm3
PC3  NFvhO4RHfW6ldHnvckBCe3OjeR?= MmW3NE4y|ryP NUO0WXQzPDiq NIrSO41FVVOR MYfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M2jtT|I2PDN2OUm3
A431 Mn\hRZBweHSxc3nzJGF{e2G7 M4rYSVIwOTBxNUCvNVAxdk1? M3faV|Q5cA>? NVPaN4hYTE2VTx?= NXzye5ZEcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MYOyOVM4OTB4OR?=
A431 MWDGeY5kfGmxbjDBd5NigQ>? M3WyVlUxdk1? MYmyM|YwOTJxMkTo MYXEUXNQ MkHLZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w MV2yOVM4OTB4OR?=
MDA-MB-231 NHfNe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vpfVAuPjBybl2= M3;vWFI1cA>? NHLoNFVFVVOR MoXjTWM2OCCxZjCxNFBvVQ>? NITGWYEzPTF7MkeyNS=>
MCF7 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[1NE03ODCwTR?= NW\JXmlPOjSq M4rTU2ROW09? M3HaemlEPTBib3[gO|VvVQ>? MnfuNlUyQTJ5MkG=
SKOV-3 M1:2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnQcHkyNTFyzszN MnLBNlRp NUi0boVyTE2VTx?= M1rRTWlEPTBib3[gOU43|ryP NFrLfWczPTF4OUS5NS=>
A549 NVuxOmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfSW2oyNTFyzszN MWKyOIg> M2LwfmROW09? MmDsTWM2OCCxZjCzMlLPxE1? M{TPZ|I2OTZ7NEmx
SKOV-3 M3HmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjCellmOC5zLUJOwG0> NXH3SFg5PDiq NV;P[HZbTE2VTx?= MVPJR|UxKG:oIECuO:69VQ>? M1[2T|I2OTZ7NEmx
A549 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3aZXkxNjFvMd88US=> MVm0PIg> MV7EUXNQ MUjJR|UxKG:oIECuNljPxE1? MmC2NlUyPjl2OUG=
SKOV-3 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMlAyNTBwOd88US=> NEHJXnI4Omh? M2rYW2ROW09? M1HvPWlEPTBib3[gNE4{Os7:TR?= MmPzNlUyPjl2OUG=
A549 NGX3bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC1O2lPOC5yMT2wMlnPxE1? MXm3Nog> MV;EUXNQ NYnEeGI4UUN3MDDv[kAxNjB4zszN Mn:yNlUyPjl2OUG=
HeLa MYfGeY5kfGmxbjDBd5NigQ>? NX22eppROjVybl2= NULOWFBqOT[q NHz0cYZFVVOR Mm\SbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= M4jFTlI2OTF4Nki4
CNE2 NHPK[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLONVAxNTZyMH7N M{HSelI1NzR6L{eybC=> Ml33bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXKyOFk3QTlyMR?=
PC3 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHaNVAxNTFyMEDuUS=> MmD1NlRp MmT1TWM2OCCxZjCzNFBvVQ>? Moj0NlQ5PTR4NUi=
LNCaP Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLnNVAxNTFyMEDuUS=> MWCyOIg> NWTMSYRzUUN3MDDv[kA{ODCwTR?= M4[yRVI1QDV2NkW4
HeLa  MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHuNu69VQ>? M2r6Z|Q5cA>? MVjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn MVyyOFg1PjF|NR?=
HMEC-1  MoPCSpVv[3Srb36gRZN{[Xl? MV2zNFBvVQ>? MUiyOIg> MU\pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MoXJNlQ4OTB4M{G=
HeLa MYDGeY5kfGmxbjDBd5NigQ>? M3yyXVFuVQ>? M2PHeVAvPWh? MUXhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? M3HRdlI1PzB5NEe0
ACP02 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DUZ|I2OC9|NUCvOVAxdk1? M3:3U|I1cA>? MkTN[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MVeyOFY3QDV2Nx?=
ACP03 NH[1emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6xNlUxNzN3MD:1NFBvVQ>? NFvY[4wzPGh? MonK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NGjDUGEzPDZ4OEW0Oy=>
U87 GBM NHPDWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O5S|ExOC9|MECvOVAxKG6P NHv3fZI4OiCq M{HocFExOCViZYToZY5wdA>? MVvy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= M4jjZlI1PDZ2OESx
U87 GBM MV\GeY5kfGmxbjDBd5NigQ>? MkPWNVAxNzVyMDDOcS=> Ml7ZOFghcA>? NUG1WI02OTByJTDleIhidm:u NGT4eoRKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? NV3jR4dpOjR2NkS4OFE>
RPE NIThWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuwMlIwOC52L{CuPE8yKM7:TR?= NIH6RnozPC92OD:3NkBp MkjBSG1UVw>? NHfKUotqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MUOyOFQ2PjZyMh?=
HT29  NWXTfWhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGUlJUOThyIH7N MlzuO|IhcA>? MlHwTWM2OCCxZjCxPFAhdk1? M3\pVFI1OzZ6Mk[1
hMSCs NGX4TYVHfW6ldHnvckBCe3OjeR?= MYq2MlI2KG6P NFLNVWwzPCCq NXfBRWdiTE2VTx?= M3v0PZN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= NXH3WVNqOjR|MUKzOVY>
Huh7  M3zpRmZ2dmO2aX;uJGF{e2G7 NITNeXAxNjFxMD61M|EvOCEQvF2= MWWyOIg> M{XrdpN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= MmPjNlQzPjl4N{K=
SKOV3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H4NlAvODVvMjFOwG0> MnzZNVAwOjRxNEigbC=> M4DiVWROW09? NVHoZ4VNdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MYWyOFIzOzhyMR?=
A2780 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXXNE4xPS1{IN88US=> NIDQeG8yOC9{ND:0PEBp NVzmV4dNTE2VTx?= MUTt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MV6yOFIzOzhyMR?=
SRA01/04  MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3kNE4zKM7:TR?= MYq0PEBp M3vweGROW09? MoXid5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NIHLRnEzPDF3N{i3PC=>
HLEB3 NYfveXFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLybFN{OC5{IN88US=> MWG0PEBp NVzXdWtYTE2VTx?= NH3UbJl{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MkPPNlQyPTd6N{i=
SRA01/04  NF7WTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHK[pB1OC52L{CuPEDPxE1? NYPLW3NmPDhiaB?= MXvEUXNQ MoTQbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUXLXYsxOjRzNUe4O|g>
HLEB3 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlQwOC56IN88US=> NIrsN4s1QCCq MYPEUXNQ M2fpRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHTOTlEzPDF3N{i3PC=>
HCT116 NF\w[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGToTWsxNjJizszN NWjBVI1zOTJiaB?= NYjk[Yw5\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> MWSyOFEzOjJ|MR?=
CA46 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PYbVMwPi9zMj:yOE81QCCwTR?= MXi0PEBp MVHpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh NFvTTlUzPDB4NEm1NS=>
PMNs NUK1SI17TnWwY4Tpc44hSXO|YYm= M4jzcFMxKG6P MVm0PEBp M1nYeolvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> M1rqRVI{QTh6NkG3
H1299 NWP0cZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0W|HDqM7:TdMg NEHTSlUzPC92OD:3NkBp MYHleIhidm:u MYXpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> NHf4PHIzOzlzNk[wPS=>
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HGbFAvOjVxMD61M|Eh|ryP NV\lRoRpOjRxNEivO|IhcA>? MnrV[ZRp[W6xbB?= MYnpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NWr4N29rOjN6Nke5PVE>
H1299 NV22ZVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnxZ|Z2OC5{NT:wMlUwOSEQvF2= NIC5[lUzPC92OD:3NkBp Mn7p[ZRp[W6xbB?= MV3pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MnXmNlM5Pjd7OUG=
A549 MlrURZBweHSxc3nzJGF{e2G7 NYjK[mhkOC53L{Gg{txO NEDZfmg1QCCq NULD[YNz\XSqYX7vcC=> M{S3[olv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUiyN|g3Pzl7MR?=
H1299 M2rvV2Fxd3C2b4Ppd{BCe3OjeR?= NXPRcWV3OC53L{Gg{txO MYC0PEBp NYCxdmFl\XSqYX7vcC=> NH[yeodqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXPsW5pVOjN6Nke5PVE>
SUM149PT NUTNbnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\RNk84NjVxMUCg{txO MlL1OFghcA>? MULEUXNQ NFyyb5ZqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= Mn\pNlM4QTJ4M{i=
SUM190PT NVHMfXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG1NE8yODBxMkWwJI5O MoX5OFghcA>? NUL1eIp4TE2VTx?= MlvCbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 M3zHTVI{Pzl{NkO4
HCT1 NEPNTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6zNE4zNzFwMD:1MlAh|ryP M2LBflEzNzJ2L{O2M|Q5KGh? MXPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NGL1dXAzOzd5MECwNC=>
Lovo NXfxSHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHab5VkOC5{L{GuNE82NjBizszN NHT3bmoyOi9{ND:zOk81QCCq NXjzOIFIcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MlGwNlM4PzByMEC=
AGS NX3DWIltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknaNE4xOTVvMTFOwG0> MWK3NkBp MnixbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MoDxNlM4PDVyMkS=
Huh7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHv[mx1OSEQvF2= MoDXNlQhcA>? MWjEUXNQ MXTy[YR2[2W|IHHic5V1KDJyJTD2bYFjcWyrdIpCpC=> NVHkU4M{OjN4NEO5N|M>
ECC1 NWnYRnBUTnWwY4Tpc44hSXO|YYm= MVq1NFAhdk1? M3fKPFUh\A>? NVrVfHRTTE2VTx?= NVG5WoVJcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M2DBZlI{PTNyN{[5
HEC1A M3rnc2Z2dmO2aX;uJGF{e2G7 NGH6[3Q2ODBibl2= MXO1JIQ> NFmwd5lFVVOR NF7S[W5qdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NUjNTVBWOjN3M{C3Olk>
EN1 M4LiUWZ2dmO2aX;uJGF{e2G7 MXG1NFAhdk1? MUG1JIQ> MmTlSG1UVw>? MV\pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NV3Kc|BbOjN3M{C3Olk>
MFE296 MWfGeY5kfGmxbjDBd5NigQ>? MXy1NFAhdk1? MWm1JIQ> NXrhU|c4TE2VTx?= M3HMSYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MXqyN|U{ODd4OR?=
HASMCs MkTwSpVv[3Srb36gRZN{[Xl? M3\IOlAuPTByIH7N NEHkXJk3KGR? M4XmcoRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 MoPWNlM2OTh2Nke=
U373 NVv6Z3llTnWwY4Tpc44hSXO|YYm= M2rTSVAvOjVxMD61M|Eh|ryP NIrhTHIzPCCq M4HnWYlv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF MoriNlM1PzRzN{G=
ARN8  NFrve4tHfW6ldHnvckBCe3OjeR?= NInsRoIxNjB3LUKg{txO M4XjWFI1KGh? NXexW2lUemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NHr5OYEzOzR5MEW0NC=>
MCF7 NV\XdIViTnWwY4Tpc44hSXO|YYm= MVqwMlA2NTJizszN NXzL[HFEOjRiaB?= Mny3doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MVWyN|Q4ODV2MB?=
H1299  M4L5T2Z2dmO2aX;uJGF{e2G7 MlHjNE4{O+LCk{JCpOK2VQ>? NXW0N3ZEOjRxNEigbC=> NGm0d4xFVVOR MYfpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 M4nhcVI{PDZzOUe1
H1299 MlnySpVv[3Srb36gRZN{[Xl? MoLXNE42KM7:TR?= M3rvbFQ5KGh? M33oOWROW09? NV;MN2ZtcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MYWyN|Q3OTl5NR?=
H1299 MYHGeY5kfGmxbjDBd5NigQ>? NHjWVG8xNjVizszN MUK0PEBp M3r1[2ROW09? NU\mZnNZcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= NEH4TmczOzR4MUm3OS=>
MG-63  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYNE4{KM7:TR?= M4r1WlEzNTl4IHi= NIrFbIZFVVOR M1\wbolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NF;QbpczOzR3MUixOy=>
LM8 NU\BVHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TSTFAvOyEQvF2= NHLhOYgyOi17NjDo MVjEUXNQ MnH4bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NHHwVVgzOzR3MUixOy=>
K562 NFy5b|dHfW6ldHnvckBCe3OjeR?= NH7WNXcxNjVizszN MlLPNlQhcA>? NV;vb5Rm\XSqYX7vcC=> NUjvWFlZ\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NVnQeVBzOjN2M{C5OVc>
HEL MXvGeY5kfGmxbjDBd5NigQ>? MXmwMlUh|ryP MWGyOEBp NFjST4NmfGijbn;s NFewXnpl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NVnBNWRPOjN2M{C5OVc>
HL60 NGDM[pRCeG:ydH;zbZMhSXO|YYm= NWSxSpc{OSEQvF2= NWrTRZR5OjRiaB?= Ml;ibY5lfWOnc9MgZ4VtdCCmZXH0bC=> M1TZZlI{PDByNUG5
KG1 MYfBdI9xfG:|aYOgRZN{[Xl? MkjrNUDPxE1? M4Ls[|I1KGh? MYfpcoR2[2W|wrDj[YxtKGSnYYTo MYSyN|QxODVzOR?=
Kazumi M{jDd2Fxd3C2b4Ppd{BCe3OjeR?= MW[xJO69VQ>? M{HWOlI1KGh? M1[xTIlv\HWlZYRCpINmdGxiZHXheIg> M{G4OVI{PDByNUG5
K562 NW\mfllESXCxcITvd4l{KEG|c3H5 NXeydpV3OSEQvF2= NFHkUlgzPCCq M3;Pc4lv\HWlZYRCpINmdGxiZHXheIg> MlHhNlM1ODB3MUm=
THP1 NXrIPIRKSXCxcITvd4l{KEG|c3H5 M1\MelEh|ryP NFfyTYozPCCq M2XsRYlv\HWlZYRCpINmdGxiZHXheIg> MV[yN|QxODVzOR?=
SH-SY5Y NWPhbWdbTnWwY4Tpc44hSXO|YYm= M2rP[lI2OCCwTR?= MXyxOkBp NXzFcoxO[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> MlPrNlM{OjZ2MkK=
HEK293 Ml7ZSpVv[3Srb36gRZN{[Xl? NUfhfY1pOSEEtV5CpC=> NEDxTYMyQCCqwrC= NEnVNWJqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| NXv2U3k6OjN{OES4OFg>
HTK NXPwTo11TnWwY4Tpc44hSXO|YYm= M1HqO|QxOCCwTR?= NHXj[ZQ4OiCq NGHyUVRqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MXeyN|I5PDByMh?=
HTK M2rvV2Z2dmO2aX;uJGF{e2G7 NVTXbpJ2OTByLUiwNI5O NYHqXZVxPzJiaB?= NHPjSYdjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= NX;4e|lVOjN{OESwNFI>
Caco-2  MYXGeY5kfGmxbjDBd5NigQ>? MVKxJOK2VcLi NFTTfZUzPCCq Mn\Z[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w NIjq[lczOzF7NUC3NC=>
HeLa MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG0OWt1OTByIH7N MV2yOEBp MXLEUXNQ MmP4TWM2OCCxZjCxNFBvVQ>? MlHFNlMyPjV5NEi=
HeLa NIT4T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiyOFAhdk1? M3fo[|Q5KGh? MornSG1UVw>? NYX5O5k5UUN3MDDv[kA1OG6P NXj6O4l6OjNzNkW3OFg>
HeLa M1PEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGyNEBvVQ>? MV:3NkBp NVWwUoZ2TE2VTx?= MmqyTWM2OCCxZjCyNI5O MV[yN|E3PTd2OB?=
HeLa NV7BVVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNE8{OC93MDDuUS=> MVy3NkBp MlWxSG1UVw>? NWXKW|BqcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 MnXnNlMyPjV5NEi=
MDA-MB-231 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqyOU01ODBibl2= MV[0PEBp NVnYZVF1UUN3MDDv[kAzPjNwMn7NxsA> MVeyN|A2PTF7OB?=
MCF-7  NYfLVJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnXco8zPS12MECgcm0> NVTld3puPDhiaB?= NF\2dmpKSzVyIH;mJFIzOC52bl2= M{LieFI{ODV3MUm4
ECC-1  MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXPWG1OOTByIH7N NHfMN40zPCCq MlfQ[ZRp[W6xbB?= M4K5W4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= NFvYd5YzOzB{OEiwNy=>
HEC-1A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTNOI1SOTByIH7N NWXpUHprOjRiaB?= NYTsNHhT\XSqYX7vcC=> MX3pcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? Mkm4NlMxOjh6MEO=
NHAC-kn MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki0NVAwOTByL{WwNEBvVQ>? NIn6WIwyOiCq M1[0T2ROW09? MVrJR|UxKG:oIEWwNI5O Ml7oNlMxOTd6N{G=
A549 NELWfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojTNlUxKG6P MYq2MVczKGh? M{H0emROW09? MUfjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni Moi3NlI6QTR5OEC=
MG-63 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrvOHViOzByIH7N MnjDNVIhcA>? NVm5OHZTTE2VTx?= Mk\LbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MlPJNlI4QTl|M{i=
MG-63 NGqz[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOzNFAhdk1? M3vKSFI1KGh? M3S4R2ROW09? M{e5NYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? NF72PI4zOjd7OUOzPC=>
MG-63 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDab2F2OzByIH7N M2r0eFQ5KGh? NF76cIJFVVOR MWDpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOVYm NXzhZo16OjJ5OUmzN|g>
HL60  NEHBVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiyT3UyPTBvM{WwJI5O MViyOEBp M2Pjeolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NF\DW24zOjd3M{ezPS=>
U937 NF;0XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxOVAuOzVyIH7N MmrUNlQhcA>? NX3WeXk1cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? MUWyNlc2Ozd|OR?=
SCC-6 M4\ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqyNFAuOzJyMDDuUS=> MXuxNk8zPC92ODDo NIL2WpFFVVOR M4Tue4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MX2yNlU2OjN{MR?=
U87  NEfVcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNFAuOzByIH7n MXeyOEBp MUXpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? M3TvV|IzOjdyOES5
K562 MmfrSpVv[3Srb36gRZN{[Xl? Mm[wNUDPxE1? M{XucFEzKGh? NWfESVNSTE2VTx?= MWDlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= NUTk[4hnOjJzN{mxPVg>
Reh M4rQS2Z2dmO2aX;uJGF{e2G7 M{DKUVAvOy9zIN88US=> M4PFNlEzKGh? NX\tWHdtTE2VTx?= Moni[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MUCyNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型,持续处理4周,具有有效的抗癌活性,即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症(SMA)模型鼠,导致乙酰化的 H3 和 H4组蛋白水平提高,也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠,促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时,或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火,然后使用600 μL 乙酸乙酯进行抽提,通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据,绘制合适的剂量反应曲线,而测定IC50。
细胞实验:[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3

CAS号 58880-19-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID